Skip to content
You are now leaving to visit

Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx

Akcea expects to initiate Phase 2b in patients with hypertriglyceridemia with established cardiovascular disease by the end of this year CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.